UTHR vs. NBIX

Last updated Apr 2, 2026

Compare and contrast key facts about United Therapeutics Corporation (UTHR) and Neurocrine Biosciences, Inc. (NBIX).

Performance

UTHR vs. NBIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in United Therapeutics Corporation (UTHR) and Neurocrine Biosciences, Inc. (NBIX). The values are adjusted to include any dividend payments, if applicable.

UTHR vs. NBIX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
UTHR United Therapeutics Corporation	17.04%	38.09%	60.46%	-20.93%	28.70%	42.35%	72.33%	-19.12%	-26.39%	3.15%
NBIX Neurocrine Biosciences, Inc.	-6.54%	3.90%	3.60%	10.31%	40.24%	-11.14%	-10.83%	50.53%	-7.96%	100.49%

Fundamentals

Market Cap UTHR : $27.32B NBIX : $13.59B
EPS UTHR : $27.90 NBIX : $4.69
PE Ratio UTHR : 20.44 NBIX : 28.25
PEG Ratio UTHR : 0.67 NBIX : 0.56
PS Ratio UTHR : 8.57 NBIX : 4.73
PB Ratio UTHR : 3.85 NBIX : 4.18
Total Revenue (TTM) UTHR : $3.18B NBIX : $2.86B
Gross Profit (TTM) UTHR : $2.80B NBIX : $2.81B
EBITDA (TTM) UTHR : $1.82B NBIX : $719.10M

Returns By Period

In the year-to-date period, UTHR achieves a 17.04% return, which is significantly higher than NBIX's -6.54% return. Over the past 10 years, UTHR has outperformed NBIX with an annualized return of 17.58%, while NBIX has yielded a comparatively lower 12.30% annualized return.

UTHR

• 1D: -3.83%
• 1M: 10.99%
• YTD: 17.04%
• 6M: 30.15%
• 1Y: 85.83%
• 3Y*: 36.55%
• 5Y*: 24.28%
• 10Y*: 17.58%

NBIX

• 1D: 0.62%
• 1M: 0.14%
• YTD: -6.54%
• 6M: -3.24%
• 1Y: 23.89%
• 3Y*: 9.41%
• 5Y*: 6.19%
• 10Y*: 12.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

UTHR vs. NBIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

UTHR

UTHR Risk / Return Rank: 91
UTHR Sharpe Ratio Rank: 87
UTHR Sortino Ratio Rank: 92
UTHR Omega Ratio Rank: 92
UTHR Calmar Ratio Rank: 94
UTHR Martin Ratio Rank: 92

NBIX

NBIX Risk / Return Rank: 61
NBIX Sharpe Ratio Rank: 66
NBIX Sortino Ratio Rank: 58
NBIX Omega Ratio Rank: 60
NBIX Calmar Ratio Rank: 61
NBIX Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

UTHR vs. NBIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	UTHR	NBIX	Difference
Sharpe ratio Return per unit of total volatility	1.71	0.71	+0.99
Sortino ratio Return per unit of downside risk	3.11	1.13	+1.98
Omega ratio Gain probability vs. loss probability	1.43	1.16	+0.27
Calmar ratio Return relative to maximum drawdown	5.20	0.95	+4.25
Martin ratio Return relative to average drawdown	13.21	2.31	+10.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

UTHR vs. NBIX - Sharpe Ratio Comparison

The current UTHR Sharpe Ratio is 1.71, which is higher than the NBIX Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of UTHR and NBIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	UTHR	NBIX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.71	0.71	+0.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.69	0.19	+0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.50	0.31	+0.19
Sharpe Ratio (All Time) Calculated using the full available price history	0.39	0.13	+0.26

Correlation

The correlation between UTHR and NBIX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

UTHR vs. NBIX - Dividend Comparison

Neither UTHR nor NBIX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

UTHR vs. NBIX - Drawdown Comparison

The maximum UTHR drawdown since its inception was -93.18%, roughly equal to the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for UTHR and NBIX.

Drawdown Indicators

	UTHR	NBIX	Difference
Max Drawdown Largest peak-to-trough decline	-93.18%	-97.21%	+4.03%
Max Drawdown (1Y) Largest decline over 1 year	-16.35%	-20.90%	+4.55%
Max Drawdown (5Y) Largest decline over 5 years	-33.00%	-42.89%	+9.89%
Max Drawdown (10Y) Largest decline over 10 years	-55.56%	-46.39%	-9.17%
Current Drawdown Current decline from peak	-3.83%	-14.82%	+10.99%
Average Drawdown Average peak-to-trough decline	-35.52%	-44.05%	+8.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.43%	8.59%	-2.16%

Volatility

UTHR vs. NBIX - Volatility Comparison

United Therapeutics Corporation (UTHR) has a higher volatility of 17.27% compared to Neurocrine Biosciences, Inc. (NBIX) at 6.97%. This indicates that UTHR's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	UTHR	NBIX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.27%	6.97%	+10.30%
Volatility (6M) Calculated over the trailing 6-month period	27.12%	23.03%	+4.09%
Volatility (1Y) Calculated over the trailing 1-year period	50.58%	33.89%	+16.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	35.31%	32.22%	+3.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.33%	39.43%	-4.10%

Financials

UTHR vs. NBIX - Profitability Comparison

The chart below illustrates the profitability comparison between United Therapeutics Corporation and Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a gross profit of 686.80M and revenue of 790.20M. Therefore, the gross margin over that period was 86.9%.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported an operating income of 356.70M and revenue of 790.20M, resulting in an operating margin of 45.1%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a net income of 364.30M and revenue of 790.20M, resulting in a net margin of 46.1%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.